It is derived from the following steps.
- 专利权人:
- JANSSEN PHARMACEUTICA N.V.
- 发明人:
- BRESLIN HENRY J,HE WEI,KAVASH ROBERT W
- 申请号：
- CY111100920
- 公开号：
- CY1111858T1
- 申请日:
- 2011.09.22
- 申请国别(地区):
- CY
- 年份:
- 2015
- 代理人:
- 摘要：
- Η παρούσα εφεύρεση αναφέρεται σε νέες ενώσεις ως διαμορφωτές, ανταγωνιστές, και αγωνιστές υποδοχέα οπιοειδών χρήσιμες για τη θεραπευτική αγωγή διαμορφούμενων από οπιοειδή διαταραχών όπως άλγος και γαστρεντερικές διαταραχές.The present invention relates to a novel compound as an opioid receptor agonist and antagonist of a modulator for the treatment of delta_alpha_rho___from Opiates and gastrointestinal diseases, such as diseases such as pain.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
- USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OF PREVENTION OF TOLL-LIKE RECEPTOR-4-ASSOCIATED DISORDERS
- Use of Toll-like receptor-9 agonists, Toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of Toll-like receptor-4-associated disorders
- PPAR COMPOUNDS FOR THE USE IN THE TREATMENT OF FIBROZAL DISEASES
- One way to treat or improve metabolic disorders is to use an agonist of GLP-1 receptor, which binds to an antagonist of the G Á strico receptor.
